Κλινικές Μελέτες
Long-Term Treatment of Overweight and Obesity with Polyglucosamine (PG L112): Randomized Study Compared with Placebo in Subjects after Caloric Restriction
Short-term treatment of overweight and obesity with polyglucosamine (PG) was
found to be more effective than placebo and orlistat in double-blind clinical studies.
Information for professionals
Guideline-based use and efficacy of the lipid binders formoline L112 and formoline L112 EXTRA in the therapy of overweight and obesity
Randomised, double-blind, clinical investigation to compare orlistat 60 milligram and a customized polyglucosamine, two treatment methods for the management of overweight and obesity
The efficacy of a non-prescription drug to support weight loss programs has yet to be compared.
This clinical trial investigates the comparability of orlistat 60 milligram (mg) and polyglucosamine.
![A single oral dose of a polyglucosamine influences the bioavailability of [9-(14)C]-Oleic acid in adult female Göttingen minipigs photo](https://formoline.gr/wp-content/uploads/2023/02/A-single-oral-dose-of-a-polyglucosamine-influences-the-bioavailability-of-9-14C-Oleic-acid-in-adult-female-Gottingen-minipigs.png)
A single oral dose of a polyglucosamine influences the bioavailability of [9-14C]- Oleic acid in adult female Göttingen minipigs
The objective of this study is to investigate the influence of polyglucosamine on the bioavailability of the model compound [9-14C]-oleic acid in female Göttingen minipigs.
Efficacy of polyglucosamine for weight loss—confirmed in a randomized double-blind, placebo-controlled clinical investigation
The purpose of this clinical study was to ascertain whether low molecular weight chitosan polyglucosamine is able to produce significantly better weight loss than placebo.
Οδηγίες χρήσης
Διαβάστε προσεκτικά αυτές τις οδηγίες χρήσης πριν τη λήψη του formoline L112 EXTRA.